PreciseDx is led by the foremost experts in the use of artificial intelligence in systems pathology. The Company’s leaders have deep expertise in diagnostics, pathology, innovative technology, and business and are further supported by a world-renowned Clinical Advisory Board comprised of distinguished clinicians.
Wayne Brinster is Chief Executive Officer of PreciseDx, and is a recognized, successful serial CEO. Prior to joining PreciseDx in 2021, Wayne was President and CEO of MedTest, where he orchestrated a complete business reorganization to align with a more strategic, market-focused vision and growth strategy. Prior to MedTest, Wayne was President and CEO of Wheaton Industries / DWK for five years where he led a major company restructuring, including new acquisitions and European expansion, generating sales growth and EBITDA improvement. Both assignments resulted in successful exits to market leading strategic purchasers. Prior positions include Vice President and General Manager of the Cancer Diagnostic group, where he led the worldwide effort to develop and release several diagnostic tests for cancer using both imaging and molecular markers. Wayne had full P&L responsibility for R&D, Regulatory, Quality, Sales, Marketing and Supply Chain management. Additional positions include Vice President and General Manager at Becton Dickinson and Vice President of Growth and Strategy at BD Diagnostics. Wayne holds a Bachelor of Science from the University of Miami, as well as several commercial board and leadership positions.
Dr. Zeineh is a co-founder and currently Chief Technology Officer of PreciseDx, where he brings deep expertise in microscopy technology research and development. Prior to his role at PreciseDx, Dr. Zeineh held a number of technology leadership positions, including CSO for Clarient, CTO/CSO for Carl Zeiss Microimaging AIS, CIO for Aureon Biosciences, and co-founder of Trestle Corporation. Dr. Zeineh graduated Summa Cum Laude from the University of California at Irvine in Biological Sciences, and received his medical degree from the University of California at San Diego. He is also a prolific inventor and holds more than 30 patents and patent applications.
Dr. Fernandez is a co-founder and currently Chief Scientific Officer of PreciseDx, in addition to his position as Adjunct Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at the Mount Sinai Health System. He received his medical degree from Drexel University College of Medicine and completed his residency in anatomic and clinical pathology as well as fellowships in surgical pathology and cytopathology from New York University School of Medicine.
Dr. Fernandez has spent the last seven years as Associate Professor at Mount Sinai building and developing the PreciseDx team and platform. Before that, he was in industry as the Medical Director for Roche Tissue Diagnostics’ (Ventana) Digital Pathology group, Vice President for Pathology and Research and Development at Aureon Biosciences, and a Staff Pathologist at Genzyme Genetics, where he specialized in oncologic pathology and tissue biomarkers.
Bradley Gendell is Chief Financial Officer of PreciseDx. Gendell brings more than 30 years of financial management and growth experience, most recently as Managing Director of 3SPOKE Capital, a private investment firm focused on late-stage venture investments. Prior to 3SPOKE, Gendell cultivated his skills in financial operations and financing growth companies through a variety of management roles. He was a Vice President of Warburg Pincus, one of the world’s leading venture capital and private equity investment firms. Gendell also launched his own hedge fund, Acclivity Capital Management, where he served as Managing Principal and Portfolio Manager. He began his career as an investment banker at Morgan Stanley. Gendell earned his Bachelor of Arts degree from Williams College, and holds a Masters in Business Administration from Harvard Business School.
Dr. Donovan is a co-founder of PreciseDx, and currently serves as Vice-chair and Professor of Translational Research in the Department of Pathology at the University of Miami. In addition to a previous academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years of experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals.
Most recently, he has served as Chief Medical Officer of Renalytix, Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc., and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan earned his Bachelor of Science degree in Zoology, a Master of Science degree in Endocrinology, and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his medical degree from the Rutgers New Jersey Medical School.
Dr. Cordon-Cardo is a co-founder and Chairman of the Advisory Board of PreciseDx, and currently serves as Professor and Chair System-Wide of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai Health System. From 1987 to 2006 Dr. Cordon-Cardo was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology and served as its first Director; scaling the academic ranks from Assistant to Professor of Pathology at Weill Cornell Medical College, Cornell University.
A pioneer of the oncologic molecular pathology discipline, Dr. Cordon-Cardo has helped establish a deeper understanding of the mechanisms of human cancers and new targets for cancer therapeutics, enhancing the vision of personalized medicine. Dr. Cordon-Cardo earned his medical degree from the Autonomous University of Barcelona (1980), and his Ph.D. in Cell Biology and Genetics from Cornell University (1985).
Douglas P. Malinowski, Ph.D., is the Vice President of Clinical Affairs at PreciseDx and brings over 40 years of experience and expertise in technology development and clinical diagnostics. Prior to joining PreciseDx, he held various leadership positions at BD Diagnostics, BD Gene, TriPath Oncology, and the BD Corporate Research Center. Doug graduated Magna Cum Laude from Notre Dame University with a degree in Chemistry. He received a Doctor of Philosophy (Ph.D.) degree in Biochemistry and Enzymology from Duke University and a Postdoctoral Fellowship in Biochemistry and Molecular Biology from the University of Washington. Doug’s career has focused on the identification of new opportunities in clinical diagnostics related to molecular oncology and microbial genomics. These specialties have led to multiple technical solutions, novel diagnostic products, and strategic innovations which addressed unmet clinical needs in cancer detection, disease characterization, and patient management.
Rebecca E. DeAngel, Ph.D, MPH, is the Senior Director of Strategic Partnerships at PreciseDx. Having spent more than 12 years in the medical and academic spaces studying oncology and respiratory functions, she brings a deep passion for innovation in clinical medicine and its ability to improve patients’ health and experiences. Dr. DeAngel served as an Associate Director/Senior Medical Science Liaison at Takeda Oncology before coming to PreciseDx. Before her time with Takeda, she worked at Bristol Myers Squibb as Immuno Oncology Field Medical Scientist and Hematology/Oncology Medical Science Liaison. Dr. DeAngel also served as a Council Member with the Gerson Lehrman Group and a Senior Scientist at Terapio championing complex, multi-step preclinical testing. Dr. DeAngel attended Universidad Adventista de las Antillas, graduating with a BS and AS in Biology and Respiratory Therapeutics. She went on to complete her MPH at Loma Linda University in Epidemiology followed by completing her Ph.D. in Molecular Nutrition-Cancer Biology and her Postdoctoral fellowship at The University of Texas at Austin.
Ted M. Diehl is Vice President of Commercial Development at PreciseDx. Diehl is a highly accomplished oncology executive with over 20 years of leadership experience in business development, commercialization, and revenue generation. Prior to joining PreciseDx, Diehl held various executive positions at Massive Bio in New York City, Sema4, IBM Watson Healthcare, Genomic Health, Inc., Sanofi, and TAP Pharmaceutical Products Inc. Diehl graduated from Immaculata University with a Bachelor of Arts in Human Resource Management and in Organizational Dynamics and is earning his masters in Executive Leadership from Liberty University. Additionally, he obtains an annual Oncology/Biotechnology Certification through the NCCN Academy and is a Certified Medical Representative through the CMR Institute, University of Medicine and Dentistry of New Jersey. Through his experience, Diehl has been successful in pioneering oncology market entry for both molecular diagnostic testing and AI utility. His expertise encompasses overcoming the challenges of introducing innovative technologies and creating collaborations between commercial and scientific teams to implement strategies for both commercial success and clinical standards of care.